Gent

• Study to Evaluate the Safety and Efficacy of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia Ended recruitment
  2023-509170-33-00 5 2021-11-23 Classic Congenital Adrenal Hyperplasia (CAH)
• A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in … Ended recruitment
  2023-506518-33-00 5 2021-11-10 Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• An International, Randomized, Double-Blind, Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Pl … Ended recruitment
  2023-509396-16-00 5 2021-11-08 Metastatic Castration-Resistant Prostate Cancer
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic … Ended recruitment
  2023-506257-37-00 5 2021-10-29 Active Psoriatic Arthritis
• Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Ended recruitment
  2023-506177-35-00 11 2021-10-23 Ovarian, fallopian tube, or primary peritoneal carcinoma.
• A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended recruitment
  2023-507130-24-00 5 2021-10-22 Neovascular age-related macular degeneration (nAMD)
• A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gas … Ended recruitment
  2023-510319-20-00 5 2021-10-21 Gastroesophageal Adenocarcinoma (GEA)
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa … Ended recruitment
  2023-503441-55-00 4 2021-10-14 Relapsed/Refractory Multiple Myeloma
• A Phase 3 Trial of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treat … Ended recruitment
  2023-507698-16-00 5 2021-10-14 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322
• EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER … Ended recruitment
  2023-506786-63-00 5 2021-09-30 Breast Cancer
• A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET Ended recruitment
  2023-508723-12-00 5 2021-09-27 gastroenteropancreatic neuroendocrine tumors
• Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended recruitment
  2024-510809-28-00 5 2021-09-27 Metastatic Castration-sensitive Prostate Cancer
• An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic … Ended recruitment
  2024-514905-79-00 9 2021-09-17 Metastatic pancreatic ductal adenocarcinoma
• Atacicept in Subjects with IgA Nephropathy (ORIGIN and ORIGIN 3) Ended recruitment
  2023-503772-24-00 10 2021-09-15 IgA Nephropathy
• An Open-Label Extension and long-term efficacy and safety monitoring study of patients with Crohn's disease previously included in the loss … Ended recruitment
  2024-514326-23-00 11 2021-09-10 Crohn's disease
• A Phase 2 Study of Avutometinib (VS-6766) Alone and In Combination with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAM … Ended recruitment
  2024-516986-35-00 4 2021-09-06 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
• PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therap … Ended recruitment
  2023-507772-50-00 5 2021-06-16 PSMA-positive metastatic castration-resistant prostate cancer
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr … Ended recruitment
  2023-504684-16-00 5 2021-06-05 follicular lymphoma (FL) and marginal zone lymphoma (MZL)
• Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive … Ended recruitment
  2023-505249-24-00 5 2021-05-27 HER2-positive metastatic breast cancer
• A study to evaluate the safety and tolerability of seladelpar in subjects with primary biliary cholangitis Ended recruitment
  2024-511753-22-00 5 2021-05-26 Primary Biliary Cholangitis
• A Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy in Participants with St … Ended recruitment
  2023-508372-10-00 4 2021-05-19 Non small Cell Lung cancer
• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER … Ended recruitment
  2023-503995-26-00 5 2021-05-11 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer
• Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended recruitment
  2024-510620-39-00 5 2021-04-19 Advanced RCC with clear cell component

Showing 601–624 of 904 trials